Klin Farmakol Farm. 2011;25(2):80-85

Tocilizumab - the contribution of interleukin-6 blockade

Pavel Jeremiáš
Oddělení klinické farmakologie FN Plzeň

Tocilizumab (TCZ) is a novel biological drug blocking effect of interleukin-6, important pleitropic cytokin, that plays important part in

etiopatogenesis of rheumatoid arthritis and other inflammatory diseases. In travenous tocilizumab is given to patiens with rheumatoid

arthritis at dose of 8 mg/kg every four weeks. Clinical trials confirmed effect of tocilizumab in different groups (insufficient response to

methotrexate, other conventional disease-modifying antirheumatic drugs, failure of tumor necrosing factor inhibitors). Tocilizumab is

the first biological drug with proven higher clinical effect in monotherapy compared with methotrexate. Tocilizumab decreases affection

aktivity assessed by evaluated indexes and also decelerate radiographic progression. European Medicine Agency approved tocilizumab

in combination with methotrexate for the moderate and severe forms of active rhematoid arthritis patiens, who failed or did not tolerate

traditional or biological disease modifying drugs. Tocilizumab has comparable safety profile in confrontacion with other biologics.

Keywords: rheumatoid arthritis, interleukin 6, biological treatment, tocilizumab

Published: June 20, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jeremiáš P. Tocilizumab - the contribution of interleukin-6 blockade. Klin Farmakol Farm. 2011;25(2):80-85.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-872. Go to original source... Go to PubMed...
    2. Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Čes Revmatol 2010; 4: 182-191.
    3. Vander Cruyssen B, Van Looy S, Wyns B, et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 2006; 8: 112. Go to original source... Go to PubMed...
    4. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993; 54: 1-78. Go to original source... Go to PubMed...
    5. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006; 8(Suppl 2): S2. Go to original source... Go to PubMed...
    6. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside, Nature Clinical Practice Rheumatology 2006; 11: 619-626. Go to original source... Go to PubMed...
    7. Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/Bcell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc. Natl Acad Sci U S A 1987; 84: 7251-7255. Go to original source... Go to PubMed...
    8. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636. Go to original source... Go to PubMed...
    9. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276. Go to original source... Go to PubMed...
    10. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 1993; 90: 11924-11928. Go to original source... Go to PubMed...
    11. Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheumatol 2003; 48: 1521-1529. Go to original source... Go to PubMed...
    12. Jourdan M, Bataille R, Seguin J, et al. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheumatol 1990; 33: 398-402. Go to original source... Go to PubMed...
    13. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19: 281-286. Go to original source... Go to PubMed...
    14. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5: 1731-1740. Go to original source... Go to PubMed...
    15. Fonseca JE, Santos MJ, Canh?o H, et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-542. Go to original source... Go to PubMed...
    16. www.emea.europa.eu.
    17. Maini RN, Tailor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patiens with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817-2829. Go to original source... Go to PubMed...
    18. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-7306. Go to original source... Go to PubMed...
    19. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis: a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-997. Go to original source... Go to PubMed...
    20. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-19. Go to original source... Go to PubMed...
    21. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010; 69: 88-96. Go to original source... Go to PubMed...
    22. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.Arthritis Rheum 2010; 63: 609-621. Go to original source... Go to PubMed...
    23. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-2980. Go to original source... Go to PubMed...
    24. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-1523. Go to original source... Go to PubMed...
    25. Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010; 39: 425-441. Go to original source... Go to PubMed...
    26. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009; 68: 1580-1584. Go to original source... Go to PubMed...
    27. Burmestre GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2010 Dec 27. (Epub ahead of print). Go to original source... Go to PubMed...
    28. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a cochrane systematic review. J Rheumatol 2011; 38: 10-20. Go to original source... Go to PubMed...
    29. Genentech Actemra(R). Prescribing Information. Available at: http://www.gene.com/gene/products/information/actemra/pdf/pi.pdf.
    30. Patel AM, Moreland LW, Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy. Drug Des Devel Ther 2010; 4: 263-278. Go to original source... Go to PubMed...
    31. Genentech. Actemra (tocilizumab) injection prescribing information. South San Francisco, CA; 2010 Jan.
    32. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011; 50: 552-562. Go to original source... Go to PubMed...
    33. Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996; 224: 647-664. Go to original source... Go to PubMed...
    34. Yamanaka H, Nishimoto N, Inoue E, et al. Incidence of malignancies in Japanese rheumatoid arthritis patients treated with tocilizumab in comparison to those in an observational cohort Japanese patients and a Japanese population database. Ann Rheum Dis 2007; 66(Suppl II): 122.
    35. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer. Implications for translational therapeutics. Cancer 2007; 110: 1911-1928. Go to original source... Go to PubMed...
    36. van Vollenhoven RFSD, Furie R, Krasnow I, et al. Long-term safety and tolerability of tocolizumab in patients with rheumatoid arthritis and a mean treatment duration of 2.4 years. Proceedings of the American College of Rheumatology Annual Scientific Meeting; 2009 Oct 17-21. Philadelphia, PA.
    37. Koike R, Harigai M, Atsumi T, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 2009; 19: 351-357. Go to original source... Go to PubMed...
    38. Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010; 3: 81-89. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.